View Post

NAB-Paclitaxel Examined Against Solvent-Based Paclitaxel in Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Dave Levitan From: cancernetwork.com Patients who took nanoparticle albumin-bound (NAB)-paclitaxel had significantly better invasive disease-free survival (iDFS) compared with those who took solvent-based (sb)-paclitaxel as neoadjuvant therapy for primary breast cancer. Previously, NAB-paclitaxel was found to be more effective than sb-paclitaxel in metastatic breast cancer, and earlier results showed an improved pathologic complete response rate (pCR) in the early …

View Post

UT Southwestern Researchers find evidence a cancer drug may be extended to many more patients

In In The News by Barbara Jacoby

Source: UT Southwestern Medical Center From: PR Newswire A new molecular mechanism discovered by UT Southwestern researchers indicates that drugs currently used to treat less than 10 percent of breast cancer patients could have broader effectiveness in treating all cancers where the drugs are used, including ovarian and prostate cancers. The new study also revealed a potential biomarker indicating when …

View Post

AI for Breast Cancer Diagnosis: The First FDA Cleared System Is Here

In In The News by Barbara Jacoby

By: Mariam Haider From: parentology.com From apps that scan for sun damage to devices that restore eyesight, Artificial Intelligence (AI) is changing how we approach healthcare. The latest in this ever-growing list: AI for breast cancer diagnosis. QuantX, created by Paragon Biosciences and Qlarity Imaging, is an AI-based breast cancer diagnosis system. It is the first ever cleared by the …

View Post

Zhang group identifies gene that may make triple-negative breast cancer cells vulnerable to existing drug

In In The News by Barbara Jacoby

Source: University of Notre Dame From: newswise.com Certain therapies that have proven effective in treating some types of breast cancers are ineffective for women diagnosed with triple-negative breast cancer (TNBC). In fact, there is limited targeted drug therapy for this type of breast cancer — the most aggressive type, diagnosed in about 20 percent of breast cancer patients. But a …

View Post

Ongoing Study Will Examine Cardiac Toxicity of Breast Cancer Treatment

In Clinical Trials by Barbara Jacoby

By: Brielle Benyon From: curetoday.com Certain breast cancer treatments could lead to heart problems down the line though unanswered questions still remain, according to recent research presented at the 2019 American Society of Clinical Oncology Annual Meeting. “We see that about a third of women, after treatment ends, are still living with fatigue and reduced exercise capacity. That puts them …

View Post

Delay from breast cancer diagnosis to chemotherapy after an operation may shorten survival

In In The News by Barbara Jacoby

By: American College of Surgeons From: medicalxpress.com Women with breast cancer should start postoperative chemotherapy, when recommended, ideally within four months of their cancer diagnosis because new study findings show that waiting longer is associated with poorer overall survival. The study, which used nationwide data, is published as an “online first article” on the Annals of Surgical Oncology website in …

View Post

Breast cancer gene mutation clinical trial to take place in Australia

In Clinical Trials by Barbara Jacoby

By: Meagan Dillon and Leah MacLennan From: abc.net.au Breast cancer is a disease that predominantly impacts women, but it is not unheard of for men to also carry a rare genetic mutation that significantly increases the risk. Helen Hicks’s husband Tony Ransom is in that category — but the Adelaide couple will not know if the mutation has been passed …

View Post

Key Trials Showcase the Utility of Neratinib in HER2+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Caroline Seymour From: onclive.com Given the number of prophylactic interventions that are now available, counseling patients with early-stage HER2-positive breast cancer on the benefit of extended adjuvant therapy with neratinib (Nerlynx) or considering its use in those with central nervous system metastases could be beneficial, said Michel Velez, MD. “We know that neratinib has value in the extended adjuvant …